Abcam, ab258699, Human SPHK2 knockout HEK-293T cell lysate

Size: 1Kit
SPHK2 KO cell lysate available now. KO validated by Western blot. Free of charge wild type control included. Knockout achieved by using CRISPR/Cas9, 1 bp insertion in exon1.
Key facts
Cell type:HEK-293T,
Species or organism:Human,
Tissue:Kidney,
Knockout validation:Sanger Sequencing,Western blot,
Mutation description:Knockout achieved by using CRISPR/Cas9, 1 bp insertion in exon1.

Product details:
Knockout cell lysate achieved by CRISPR/Cas9.
REACH authorisation
Abcam has not and does not intend to apply for the REACH Authorisation of customers' uses of products that contain European Authorisation list (Annex XIV) substances.
It is the responsibility of our customers to check the necessity of application of REACH Authorisation, and any other relevant authorisations, for their intended uses.
Lysate preparation:
Our lysates are made using RIPA buffer to which we add a protease inhibitor cocktail and phosphatase inhibitor cocktail (ratio: 300:100:10).
This means that the protein of interest is denatured.
If you require a native form of the protein please use the live cell version. Please refer to our lysis protocol for further details on how our lysates are prepared.
User storage instructions:
Lyophilizate may be stored at 4°C. After reconstitution, store at -20°C for short-term storage or -80°C for long-term storage.
This product is subject to limited use licenses from The Broad Institute, ERS Genomics Limited and Sigma-Aldrich Co. LLC, and is developed with patented technology. For full details of the licenses and patents please refer to our
limited use license
patent pages

Properties and Storage Information:
Gene name-SPHK2, Gene editing type-Knockout, Gene editing method-CRISPR technology, Knockout validation-Sanger Sequencing, Western blot, Shipped at conditions-Ambient - Can Ship with Ice, Appropriate short-term storage conditions--20°C, Appropriate long-term storage conditions--20°C

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
SPHK2 also known as sphingosine kinase 2 is an enzyme responsible for the conversion of sphingosine to sphingosine-1-phosphate (S1P). This enzyme weighs approximately 68 kDa and is expressed in a wide range of tissues including liver kidney and brain. The catalytic activity of SPHK2 involves the phosphorylation of sphingosine which plays a part in the modulation of various cellular processes.
Biological function summary
SPHK2 influences cell growth survival and differentiation by generating sphingosine-1-phosphate a signaling lipid. It functions independently or in association with other proteins but it is not always a part of a larger complex. The generated S1P acts as a signaling molecule both inside and outside of cells affecting processes like apoptosis and inflammation.
Pathways
SPHK2 is a significant player in the sphingolipid signaling pathway and impacts the MAPK/ERK pathway. These pathways collectively regulate cellular proliferation and apoptosis. SPHK2 works in conjunction with SPHK1 a closely related sphingosine kinase in these signaling routes. These kinases together help to balance the levels of sphingosine and S1P which is essential for maintaining cellular homeostasis.
SPHK2 has been linked to cancer and inflammatory diseases. The overexpression of SPHK2 can result in increased levels of sphingosine-1-phosphate promoting cancer cell survival and resistance to chemotherapy. In addition SPHK2's involvement in inflammation suggests roles in conditions like rheumatoid arthritis where it might interact with TNF-α related signaling pathways. These connections highlight SPHK2 as a potential target for therapeutic intervention in such diseases.